Non-Variola Orthopoxvirus (NVO) Laboratory Testing by Demographics
As of here, laboratory testing data from one commercial laboratory for the period 7-16-2022 through 9-25-2022 have been updated, and data subsequent to 9-25-2022 have been added. The number of tests and test positivity rates reported may differ from previously published results.
Data from Laboratory Response Network laboratories and 4 commercial laboratories using the CDC non-variola orthopoxvirus (NVO) assay and one commercial laboratory using a non-variola orthopoxvirus and mpox multiplex assay. Due to low testing volume data before May 29, 2022, are omitted.
Data on sexual orientation or gender identity are not available in laboratory test results reported to CDC. Figure includes test results for specimens with “F” or “M” reported for sex.
Total tests include all specimens tested, including positive, negative, equivocal, and inconclusive results.
- Positivity rate based on specimens tested, not patients. Most patients have multiple specimens tested. Positivity rate is calculated as (number of positive specimens)/(number of positive +negative specimens) per week. Results that are equivocal or inconclusive are not included. Changes in the week-to-week positivity rates may be related to sample size. Estimates derived from small sample sizes should be interpreted with caution.
Line-listed data replaced aggregate data for one commercial laboratory beginning with the week ending 7-16-2022. This resulted in updates to the number of specimens tested and positivity rates during these weeks.